Innovation Observatory > Reports > Drugs > Benralizumab for Chronic Obstructive Pulmonary Disease (COPD)

< Back

Benralizumab for Chronic Obstructive Pulmonary Disease (COPD)


Respiratory Disease and Thoracic Surgery

December 2017

Benralizumab is a new drug being developed for the treatment of chronic obstructive pulmonary disease. It is administered by injection under the skin and acts by targeting specific proteins that
causes the airway to narrow. If benralizumab is licensed for use in the UK, it could be a new treatment option for patients with chronic obstructive pulmonary disease that may improve quality of life and reduce the number of exacerbations.

Innovation Observatory Voice 0

Leave a Reply

Your email address will not be published. Required fields are marked *

Post Comment

Connect to the Innovation Observatory



Related Information

Benralizumab for COPD

Load More Related Posts
Get Alerts